Therapy of Autoinflammatory Syndromes

Overview

Journal J Allergy Clin Immunol

Specialty Allergy & Immunology

Date 2009 Dec 17

PMID 20004774

Citations 40

Authors

Hal M Hoffman

Affiliations

Soon will be listed here.

Abstract

The therapy of autoinflammatory syndromes is an excellent example of the power of translational research. Recent advances in our understanding of the molecular and immunologic basis of this newly identified classification of disease have allowed for the application of novel, effective, targeted treatments with life-changing effects on patients. Although colchicine and TNF-alpha inhibitors are important therapies for specific autoinflammatory syndromes, the novel IL-1-targeted drugs are particularly effective for many of these diseases. Recently, the pharmaceutical industry has adopted a strategy of confirming the efficacy of new targeted drugs in often-ignored patients with orphan diseases, and US Food and Drug Administration policies have allowed for accelerated approval of these drugs, creating a win-win situation for patients and industry. This article reviews the general approach to the therapy of autoinflammatory diseases, focusing on current approved therapies and novel approaches that might be used in the future.

Citing Articles

Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders.

Baglaenko Y, Wagner C, Bhoj V, Brodin P, Gershwin M, Graham D Camb Prism Precis Med. 2024; 1:e25.

PMID: 38550937 PMC: 10953750. DOI: 10.1017/pcm.2023.14.

The NLRP1 inflammasome in skin diseases.

Burian M, Schmidt M, Yazdi A Front Immunol. 2023; 14:1111611.

PMID: 36911693 PMC: 9996011. DOI: 10.3389/fimmu.2023.1111611.

Activation and Regulation of NLRP3 by Sterile and Infectious Insults.

Banerjee S, Chatterjee A, Gupta S, Nagar A Front Immunol. 2022; 13:896353.

PMID: 35663964 PMC: 9161712. DOI: 10.3389/fimmu.2022.896353.

The unusual experience of managing a severe COVID-19 case at home: what can we do and where do we go?.

Cherrez-Ojeda I, Vanegas E, Felix M BMC Infect Dis. 2020; 20(1):862.

PMID: 33213364 PMC: 7675380. DOI: 10.1186/s12879-020-05608-0.

Inflammasome inhibition under physiological and pharmacological conditions.

Caseley E, Poulter J, Rodrigues F, McDermott M Genes Immun. 2020; 21(4):211-223.

PMID: 32681062 DOI: 10.1038/s41435-020-0104-x.

References

Hoffman H, Throne M, Amar N, Sebai M, Kivitz A, Kavanaugh A . Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008; 58(8):2443-52. DOI: 10.1002/art.23687. View

Dinarello C . The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2004; 20(5 Suppl 27):S1-13. View

Goldbach-Mansky R, Shroff S, Wilson M, Snyder C, Plehn S, Barham B . A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008; 58(8):2432-42. PMC: 2875198. DOI: 10.1002/art.23620. View

Zemer D, Revach M, Pras M, Modan B, Schor S, SOHAR E . A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med. 1974; 291(18):932-4. DOI: 10.1056/NEJM197410312911803. View

Kuijk L, Govers A, Frenkel J, Hofhuis W . Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis. 2007; 66(11):1545-6. PMC: 2111630. DOI: 10.1136/ard.2007.071498. View

Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U . An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med. 2009; 360(23):2438-44. PMC: 2803085. DOI: 10.1056/NEJMoa0809568. View

Dinarello C, Chusid M, Fauci A, Gallin J, Dale D, Wolff S . Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever. Arthritis Rheum. 1976; 19(3):618-22. DOI: 10.1002/art.1780190315. View

Arostegui J, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P . NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 2007; 56(11):3805-13. DOI: 10.1002/art.22966. View

GOLDFINGER S . Colchicine for familial Mediterranean fever. N Engl J Med. 1972; 287(25):1302. DOI: 10.1056/NEJM197212212872514. View

10.

Rudinskaya A, Trock D . Successful treatment of a patient with refractory adult-onset still disease with anakinra. J Clin Rheumatol. 2006; 9(5):330-2. DOI: 10.1097/01.rhu.0000089966.48691.7f. View

11.

Hoffman H, Patel D . Genomic-based therapy: targeting interleukin-1 for autoinflammatory diseases. Arthritis Rheum. 2004; 50(2):345-9. DOI: 10.1002/art.20032. View

12.

Mitroulis I, Papadopoulos V, Konstantinidis T, Ritis K . Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med. 2008; 66(11):489-91. View

13.

Nedjai B, Hitman G, Quillinan N, Coughlan R, Church L, McDermott M . Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2009; 60(2):619-25. DOI: 10.1002/art.24294. View

14.

Hoffman H . Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin Biol Ther. 2009; 9(4):519-31. DOI: 10.1517/14712590902875518. View

15.

Simon A, Bodar E, van der Hilst J, van der Meer J, Fiselier T, Cuppen M . Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med. 2004; 117(3):208-10. DOI: 10.1016/j.amjmed.2004.02.039. View

16.

Gattorno M, Pelagatti M, Meini A, Obici L, Barcellona R, Federici S . Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008; 58(5):1516-20. DOI: 10.1002/art.23475. View

17.

Leslie K, Lachmann H, Bruning E, McGrath J, Bybee A, Gallimore J . Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol. 2006; 142(12):1591-7. DOI: 10.1001/archderm.142.12.1591. View

18.

Majeed H, Carroll J, Khuffash F, Hijazi Z . Long-term colchicine prophylaxis in children with familial Mediterranean fever (recurrent hereditary polyserositis). J Pediatr. 1990; 116(6):997-9. DOI: 10.1016/s0022-3476(05)80667-5. View

19.

Goldbach-Mansky R, Dailey N, Canna S, Gelabert A, Jones J, Rubin B . Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006; 355(6):581-92. PMC: 4178954. DOI: 10.1056/NEJMoa055137. View

20.

Botsios C . Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev. 2005; 4(3):162-70. DOI: 10.1016/j.autrev.2004.09.001. View